Search
forLearn
5 / 801 resultslearn 3 aminopropane Sulfernic acid
learn vitamin b3
learn Selenium AAC
learn AminoMar™
Research
5 / 1000+ results
research LB1139 AMP-303 injectable treatment for androgenetic alopecia: A multicenter, randomized, placebo-controlled feasibility study of a novel polysaccharide
AMP-303 safely increases hair growth in men with hair loss.
research 453 Signaling by Senescent Melanocytes Induces New Hair Growth and Informs Hair Growth-Activating Injectable for Androgenetic Alopecia
AMP-303 injections can increase hair growth in androgenetic alopecia with minimal side effects.
research 217 The adenosine-generating ecto-enzyme CD73 regulates human hair growth
The enzyme CD73 helps control human hair growth and could be targeted to treat hair growth disorders.
research 671 The adenosine-generating ecto-enzyme, CD73, functions as an intrafollicular regulator of human hair growth
CD73 may regulate hair growth and could be targeted for hair growth treatments.
research Mandibulofacial dysostosis with alopecia results from ETAR gain-of-function mutations via allosteric effects on ligand binding
Specific mutations in a receptor cause facial abnormalities and hair loss.
Community Join
5 / 48 resultscommunity New Hair Loss Cure: AMP-303 Is Back. It’s what PP405 should have been.
AMP-303 and AMP-601 are new hair loss treatments targeting dermal papilla cells, with AMP-303 showing early efficacy in transitioning vellus hairs to terminal hairs after one injection. Further clinical trials are planned, and these treatments are seen as promising due to their biologic approach and less frequent application compared to daily treatments.
community Amplifica’s AMP-303 Study Unveils New Hope for Hair Loss Treatments
AMP-303, a new injectable treatment for androgenetic alopecia, showed promising results in increasing hair count and density with minimal side effects. The treatment demonstrated significant hair regrowth and durability, offering new hope for those with hair loss.
community Amplifica AMP-303 study results are expected late this summer
Results for Amplifica's AMP-303 hair loss treatment study are expected late summer 2024. The study, fully enrolled in Q1 2024, focuses on safety and tolerability.
community Amplifica and AMP-303 clinical phase 1
Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.
community Why there are no updates from Amplifica about SCUBE3 & AMP-303?
Amplifica has not provided updates on SCUBE3 and AMP-303, raising concerns about their trial outcomes. Users also mention other treatments like Minoxidil, finasteride, RU58841, PP405, and ET-03.